NOVELTY - Photolabile ruthenium compounds are new.    USE - In the preparation of composition; for releasing an organic molecule from a photolabile compound; for making an organic molecule bioavailable to a subject; for treating disorders and diseases in a subject, where the disorders and diseases are neurological, neurophysiological, or neuromuscular diseases and conditions such as epilepsy, multiple sclerosis, diaphoresis and cancer; for enhancing the solubility of an organic molecule (claimed); in non-biological systems such as in solar cells, photocells, or an optical memory, e.g. a three dimensional optical memory; in veterinary and human medicine. The organic molecule includes drug, pharmaceutical, small biological active molecule. The diseases, disorders, pathologies, or conditions include peripheral and central nervous system disorders, neurological disorders and disorders related to it, neurodegenerative disorders and disorders related to it, epilepsy, seizures, migraines, headaches, stroke, anxiety, depression, restricted brain function, addictive disorders, neuroses, psychoses, pruritic conditions, Parkinson's disease, Huntington's chorea, cognitive disorders, memory lapses, Alzheimer's disease, dementia, dyskinesia, muscle spasms, retinopathy, vomiting, cancers, neoplasms, tumors, vascular diseases, and cardiovascular diseases. For treating autoimmune diseases such as multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis, rheumatoid arthritis, ischemic injury (e.g. caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g. hepatitis related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury) and liver cancer); toxin-induced liver disease (e.g. caused by alcohol), septic shock, cachexia and anorexia, viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft versus host (GVH) disease, acute graft rejection, and chronic graft rejection; diseases or conditions associated with abnormal and increased cell survival such as leukemia, polycythemia vera, lymphomas (e.g. Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, mesothelioma, Ewing's tumor, pancreatic cancer, medullary carcinoma, Wilm's tumor, hemangioblastoma; for stimulating epithelial cell proliferation and basal keratinocytes for the purpose of wound healing; for stimulating hair follicle production and the healing of dermal wounds; in stimulating wound healing, oral cavity wounds, diabetic ulcers, burns resulting from heat exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications associated with systemic treatment using steroids, radiation therapy, anti-neoplastic drugs and anti-metabolites; for treating AIDS, cerebellar degeneration, and prion associated disease.    ADVANTAGE - The compounds protect organic molecule such as bioactive molecule. The compounds provide valuable source for in vivo biological applications such as treatment of various diseases, conditions and disorders of the body. The compounds allow precise control of the onset of a bioactive function or a bioactivity in the body e.g. in living organs, tissues, and cells, i.e. within nanoseconds to milliseconds, with minimal harm to a biological sample, or to the body or its organ, tissue and cellular components.    DETAILED DESCRIPTION - Photolabile ruthenium compounds of formulae (V)-(VIII) are new.    L1=organic molecule having e.g. 5-membered monocyclic aromatic ring, where one of the ring's members is a nitrogen atom that forms a bond with Ru; or -SR group whose sulfur atom forms bond with Ru;    R=H, 1-18C alkyl, or aryl;    L2=e.g. CN or a labeling molecule or its active derivative connected to Ru through the nitrogen atom of: e.g. NHR9; or is P(phenyl)3;    m=1 or 2;    R9=e.g. 1-18C alkyl or -SH;    R1-R4=e.g. H, 1-18C alkyl or SH;or    R1+R2 and/or R3+R4=a carbocyclic ring substituted by at least one oxo;    X=e.g. Cl-, or (1-18C alkyl)-SO3-;    Y'=e.g. H;    L'2=e.g. P(phenyl)3, where each phenyl is substituted with e.g. -1-18C alkyl, or -SH; or is a labeling molecule or its active derivative connected to Ru through the phosphorus atom of (R9)2P or (R9O)2P;    L2a=e.g. (R9)3P; or is CN;    L1b=e.g. labeling molecule or its active derivative connected to Ru through the phosphorus atom of (R9)2P or (R9O)2P;    L2b=Cl-, phosphine, or pyridine or CN.    Full Definitions are given in the DEFINITIONS (Full Definitions) section. INDEPENDENT CLAIMS are included for the following:    (1) a method (M) for releasing an organic molecule from a Photolabile Compound, involving: exposing compound (V) to light under conditions to release the organic molecule;    (2) a method (M1) for making an organic molecule bioavailable to a subject;    (3) a vessel containing the compound (V);    (4) a kit comprising the compound (V) and instructions for use of the compound;    (5) method (M2) of treating disorders and diseases in a subject;    (6) a method (M4) for enhancing the solubility of an organic molecule; and    (7) a method (M3) for releasing fluorescent molecule from a photolabile compound, involving: exposing compound (VIII) to light to release the fluorescent molecule.